Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Navtemadlin (MDM2 Inhibitor) in Myelofibrosis. The expected timing is based on the latest available company guidance and may change.
07/30/26:- POIESIS Ph3 myelofibrosis topline data expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.